Table 2: Malonyldialdehyd and 4-hydroxynonenal concentration (nmol/g of cardiac sample; 𝑋 ± S . D .) in rat cardiac homogenates 4, 48, and 96 h after doxorubicin administration.

Time from DOX injection (h)DOX (mg/kg) or salineMethimazole (%)ANOVA
0.00000.001 (METL)0.025 (METH) 𝑃

42 2 8 . 0 1 ± 3 . 0 7 3 0 . 3 3 ± 4 . 0 6 2 9 . 1 2 ± 4 . 7 3 0.6977
5 3 0 . 3 6 ± 2 . 5 2 3 1 . 4 2 ± 3 . 5 8 2 6 . 1 1 ± 3 . 8 2 0.0706
15 3 1 . 8 1 ± 3 . 6 7 3 5 . 2 1 ± 7 . 4 0 3 3 . 9 3 ± 4 . 0 9 0.7163

482 2 5 . 8 4 ± 4 . 2 6 2 3 . 3 7 ± 3 . 9 4 2 2 . 0 1 ± 4 . 1 4 0.5945
5 2 6 . 8 5 ± 1 . 3 9 2 5 . 0 6 ± 3 . 9 0 2 5 . 8 4 ± 0 . 9 6 0.6288
15 2 9 . 8 5 ± 6 . 5 0 2 9 . 6 3 ± 7 . 8 5 3 8 . 5 0 ± 4 . 5 *0.7520

962 3 1 . 3 6 ± 1 0 . 4 5 2 2 . 4 3 ± 1 . 9 9 # 2 8 . 4 9 ± 4 . 8 3 0.0358
5 3 1 . 2 5 ± 4 . 3 3 3 2 . 2 0 ± 7 . 4 8 2 6 . 1 2 ± 4 . 9 3 0.2535
15 3 9 . 3 6 ± 3 . 3 9 * 3 5 . 4 3 ± 4 . 3 8 4 4 . 9 9 ± 1 3 . 8 7 *0.2783
0.9% NaCl 𝟐 𝟒 . 𝟖 𝟗 ± 𝟔 . 𝟕 𝟏 (control) 2 6 . 3 2 ± 3 . 2 4 2 2 . 4 8 ± 3 . 4 2

* 𝑃 < 0 . 0 5 versus control; #DOX + MET versus DOX.